Extensions

US patent 8268847 has an adjusted expiration date of April 18, 2029. This patent term was extended or adjusted by 599 days under 35 U.S.C. 154(b). Additionally, protection for the drug OPSUMIT, covered by this patent, has been extended six months for pediatric studies, indicated by a *PED designation.

The patent is a United States National Stage Application of PCT Application No. PCT/IB2007/053448, filed on August 28, 2007. This PCT application claims the benefit of PCT Application No. PCT/IB2006/052999, filed on August 29, 2006, and PCT Application No. PCT/IB2006/053857, filed on October 19, 2006.

Related Applications:

The patent has several related applications that claim priority from it. These include a number of abandoned continuation applications:

• US13/604,148, filed September 5, 2012 (Abandoned)
• US14/162,280, filed January 23, 2014 (Abandoned)
• US15/881,060, filed January 26, 2018 (Abandoned)
• US16/193,859, filed November 16, 2018 (Abandoned)
• US16/599,582, filed October 11, 2019 (Abandoned)
• US16/942,895, filed July 30, 2020 (Abandoned)
• US17/185,238, filed February 25, 2021 (Abandoned)

There are no explicitly listed "divisional applications" within the provided information.

Family Members:

US8268847 is part of a larger patent family with thirty-nine patent family members across thirty-two countries. The Google Patents entry lists several family applications in various countries, including:

• EP2059246B1 (Europe)
• JP5208113B2 (Japan)
• KR101473022B1 (South Korea)
• CN101511365B (China)
• AU2007290099B2 (Australia)
• CA2659770C (Canada)
• MX2009002057A (Mexico)
• RU2462249C2 (Russia)